micronavigation EUTOS path item Meetings path item Meetings 2009

Meetings in 2009

The Management of CML: Current treatment paradigms and future perspectives
Policlinico Universitario, Naples, 18 -19 May 2009

The Management of CML: Current treatment paradigms and future perspectives

application/pdf Agenda Current treatment paradigms and future perspectives (141KB)
Naples, May 2009

Abstracts of Session 1: First-line treatment approaches in CML - Monday 18 May
Chaired by F Pane and M Baccarani

application/pdf F. Pane: Overview (206KB)
Introduction and objectives
Keywords: CML, chronic myeloid leukemia, overview, research
application/pdf G. Saglio: Biology (3.2 MB)
The biology of CML
Keywords: CML, chronic myeloid leukemia, biology, pathophysiology
application/pdf M. Baccharani: IRIS and GIMEMA trials (384KB)
First line treatment of CML with imatinib: the IRIS trial and the GiMENA trials
Keywords: CML, chronic myeloid leukemia, first line treatment, chronic phase, imatinib
application/pdf G. Rosti: Unsatisfactory response (661KB)
Unsatisfactory treatment response: more imatinib or 2nd generation TK inhibitors?
Keywords: CML, chronic myeloid leukemia, imatinib, dasatinib, nilotinib, non response
application/pdf L. Luciano: Living with CML (1.5 MB)
Living with CML: practical management and long-term treatment effects
Keywords: CML, chronic myeloid leukemia, late effects, coping
application/pdf G. Rosti: Elderly and children (739KB)
CML in elderly patients and children
Keywords: CML, chronic myeloid leukemia, elderly, children, outcome
application/pdf A. Hochhaus: Imatinib good responder (54KB)
Clinical case presentation 1: Optimal response to imatinib treatment and management of the patient
Keywords: CML, chronic myeloid leukemia, imatinib, chronic phase, good response
application/pdf S. Saußele: Imatinib late responder (294KB)
Clinical case presentation 2: Late response to treatment
Keywords: CML, chronic myeloid leukemia, chronic phase, imatinib, late response

Abstracts of Session 2: Prognostic factors for treatment response in CML - Thuesday 19 May
Chaired by G Matrinelli and A Hochhaus

application/pdf A. Hochhaus: BCR-ABL quantitation and mutation detection (1.1 MB)
BCR-ABL quantitation and mutation detection: methods of disease monitoring and the challenge of standardization
Keywords: CML, chronic myeloid leukemia, monitoring, mutation, bcr-abl, standardization
application/pdf S. Saußele: Stem cell transplantation (1.1 MB)
The role of stem cell transplantation in CML treatment and blast phase management
Keywords: CML, chronic myeloid leukemia, stem cell transplantation, blast crisis
application/pdf FX. Mahon: Imatinib metabolism (785KB)
Metabolism of imatinib and other TK inhibitors: importance of blood level testing
Keywords: CML, chronic myeloid leukemia, imatinib, dasatinib, nilotinib, blood level, monitoring, metabolism
application/pdf A. Hochhaus: Resistance (1.4 MB)
Cellular and molecular mechanisms of imatinib resistance
Keywords: CML, chronic myeloid leukemia, resistance, pathophysiology
application/pdf G. Martinelli: Imatinib poor responder (87KB)
Clinical case presentation 3: Suboptimal response to imatinib with dose increase rescue
Keywords: CML, chronic myeloid leukemia, imatinib, poor responder, dose increase
application/pdf G. Rosti: Imatinib failure (390KB)
Clinical case presentation 4: Failure of treatment in a young high Sokal risk patient
Keywords: CML, chronic myeloid leukemia, imatinib failure, high risk

Abstracts of Session 3: Second-line treatment approaches in CML - Thuesday 19 May
Chaired by R Hehlmann and G Saglio

application/pdf G. Martinelli: Resistance (1.6 MB)
New generation TK inhibitors in patients with treatment resistance
Keywords: CML, chronic myeloid leukemia, resistance, imatinib, dasatinib, nilotinib
application/pdf F. Pane: New inhibitors front line (1.1 MB)
New generation TK inhibitors in front -line therapy
Keywords: CML, chronic myeloid leukemia, nilotinib, dasatinib, imatinib, front line
application/pdf G. Saglio: Minimal residual disease (1.8 MB)
Minimal residual disease in responding patients: therapeutic strategies
Keywords: CML, chronic myeloid leukemia, minimal residual disease, treatment
application/pdf F. Pane: ELN recommendation (1.1 MB)
Updated ELN recommendations for the management of CML
Keywords: CML, chronic myeloid leukemia, ELN recommendation, guideline, update
application/pdf F. Pane: Imatinib failure (586KB)
Clinical Case 5: Failure of treatment due to mutation
Keywords: CML, chronic myeloid leukemia, imatinib, failure, mutation
application/pdf A. Hochhaus: Pregnancy (109KB)
Clinical Case 6: Young woman with good response to imatinib wishing to get pregnant
Keywords: CML, chronic myeloid leukemia, pregnancy, imatinib
application/pdf R. Hehlmann: EUTOS (760KB)
Closing address: EUTOS for CML - an innovative collaboration between ELN and Novartis
Keywords: CML, chronic myeloid leukemia, EUTOS, summary

EUTOS Molecular Monitoring Meeting International Standardization of RQ-PCR
Berlin, Germany, 7 - 8 June 2009

EUTOS Molecular Monitoring Meeting International Standardization of RQ-PCR

application/pdf Agenda Molecular Monitoring Meeting (30KB)
Berlin, June 2009

Molecular Standardization and Mutational Analysis: Clinical Role and Current Status, Sunday 7th June 2009

Session 1: Molecular Analysis Session
Chair: N. Cross

application/pdf A. Hochhaus: Molecular monitoring (1.2 MB)
Role of molecular monitoring in clinical practice
Keywords: CML, chronic myeloid leukemia, molecular monitoring, bcr-abl
application/pdf M. Mueller: Standardization (397KB)
Standardization of molecular monitoring- rationale for EUTOS for CML
Keywords: CML, chronic myeloid leukemia, molecular monitoring, standardization, bcr-abl
application/pdf N. Cross: Reference reagents (544KB)
International standardization of RQ-PCR testing, primary reference reagents
Keywords: CML, chronic myeloid leukemia, molecular monitoring, standardization, bcr-abl, reference reagents

Session 2: Mutational Analysis Session
Chair: G. Saglio

application/pdf T. Ernst: Interlab test (422KB)
Techniques for detection of mutation, status of the interlab test
Keywords: CML, chronic myeloid leukemia, standardization, bcr-abl, interlab tests, mutations
application/pdf G. Martinelli: Decision making (1.1 MB)
Mutational analysis in clinical decision making
Keywords: CML, chronic myeloid leukemia, mutations, bcr-abl
application/pdf S. Soverini: Clinical recommendations (350KB)
Establishment of clinical recommendations for detection of mutations
Keywords: CML, chronic myeloid leukemia, mutations, recommendation, bcr-abl

ELN Frontiers Meeting: Continuing the CML Revolution: Expanding options in targeted therapy

ELN Frontiers Meeting: Continuing the CML Revolution: Expanding options in targeted therapy

application/pdf Agenda ELN Frontiers Meeting (655KB)
Barcelona, September 2009

Here you can find the slides released for the EUTOS website:↵

Saturday, 19 September 2009, Session 1
Focus on first-line therapy

application/vnd.ms-powerpoint 01_OBrien_The IRIS trial_A clinical perspective on the 7-year update.ppt (1.6 MB)
01_OBrien_The IRIS trial_A clinical perspective on the 7-year update.ppt
Keywords: IRIS, clinical trial
application/vnd.ms-powerpoint 04_Goldman_The Hammersmith study_How does it compare.ppt (1.5 MB)
04_Goldman_The Hammersmith study_How does it compare.ppt
Keywords: Hammersmith Study
application/vnd.ms-powerpoint 05_Rosti_Treatment options in first-line therapy.ppt (1.7 MB)
05_Rosti_Treatment options in first-line therapy.ppt
Keywords: Treatment options
application/vnd.ms-powerpoint 06_Steegmann_Imatinib in clinical practice.ppt (2.1 MB)
06_Steegmann_Imatinib in clinical practice.ppt
Keywords: Imatinib, clinical practice
application/vnd.ms-powerpoint 07_Appperley_Management of special CML populations.ppt (2.6 MB)
07_Appperley_Management of special CML populations.ppt
Keywords: CML, Leukemia

Saturday, 19 September 2009, Session 2
Improving the standard of care

application/vnd.ms-powerpoint 08_Pane_EUTOS for CML_Making progress in a successful collaboration.ppt (2.0 MB)
08_Pane_EUTOS for CML_Making progress in a successful collaboration.ppt
Keywords: EUTOS, CML
application/vnd.ms-powerpoint 16_17_Guilhot_Clark_Blood level testing is a necessary tool for optimizing CML management.ppt (2.9 MB)
16_17_Guilhot_Clark_Blood level testing is a necessary tool for optimizing CML management.ppt
Keywords: CML, blood level

Saturday, 19 September 2009, Session 3
Monitoring an evaluating response

application/vnd.ms-powerpoint 18_Cervantes_The ELN recommendations_New data supporting an update.ppt (1.9 MB)
18_Cervantes_The ELN recommendations_New data supporting an update.ppt
Keywords: recommendation
application/vnd.ms-powerpoint 20_Marin_Response criteria for 2nd-generation TKIs.ppt (1.4 MB)
20_Marin_Response criteria for 2nd-generation TKIs.ppt
Keywords: response criteria
application/vnd.ms-powerpoint 21_Hellmann_Interpreting the new recommendations_case in point.ppt (1.3 MB)
21_Hellmann_Interpreting the new recommendations_case in point.ppt
Keywords: recommendations, leukemia

Saturday, 19 September 2009, Session 4
Clinical implications of predictive factors

application/vnd.ms-powerpoint 23_Mayer_The importance of achieving complete cytogenetic response.ppt (2.3 MB)
23_Mayer_The importance of achieving complete cytogenetic response.ppt
Keywords: cytogenetic response, leukemia
application/vnd.ms-powerpoint 26_Soverini_A critical appraisal to to the value of in vitro data in guiding CML therapy.ppt (2.0 MB)
26_Soverini_A critical appraisal to to the value of in vitro data in guiding CML therapy.ppt
Keywords: CML, recommendations

Saturday, 20 September 2009, Session 5
Philadelphia chromosome negative chronic myeloproliferative disorders

application/vnd.ms-powerpoint 32_Escribano_Systemic mastocytosis_biology and treatment.ppt (1.9 MB)
32_Escribano_Systemic mastocytosis_biology and treatment.ppt
Keywords: mastocytosis, leukemia

Saturday, 20 September 2009, Session 6
How can we improve clinical outcome of CML patients?

application/vnd.ms-powerpoint 34_Porkka_Treatment of CML in advanced phases.ppt (1.9 MB)
34_Porkka_Treatment of CML in advanced phases.ppt
Keywords: CML, leukemia
application/vnd.ms-powerpoint 35_Hochhaus_Are 2nd-generation TKIs the preferred 2nd-line treatment option.ppt (2.4 MB)
35_Hochhaus_Are 2nd-generation TKIs the preferred 2nd-line treatment option.ppt
Keywords: TKI, treatment options
application/vnd.ms-powerpoint 36_Olavarria_Is transplantation the preferred 2nd-line treatment option.ppt (1.7 MB)
36_Olavarria_Is transplantation the preferred 2nd-line treatment option.ppt
Keywords: transplantation, leukemia
application/vnd.ms-powerpoint 39_Saglio_Eradicating the CML stem cell.ppt (2.0 MB)
39_Saglio_Eradicating the CML stem cell.ppt
Keywords: CML, stem cell
application/vnd.ms-powerpoint 40_Hehlmann_Are we approaching a cure.ppt (2.4 MB)
40_Hehlmann_Are we approaching a cure.ppt
Keywords: CML, leukemia

Created by: Schäfer , generated 2010/04/15 , last changed: 2010/04/15

 

Print this Document Sitemap   Contact  
European LeukemiaNet More ...


 
top